Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension
The purpose of this study is to determine the prognostic value of echocardiographic parameters in comparison with clinical and hemodynamic parameters in pulmonary arterial hypertension (PAH).
- Trial name
- NCT02885155
- Testing
- Echocardiography, Hemodynamic examinations (right cardiac catheterization)
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
Heart Failure, Hypertension, Pulmonary
Measurement of Endothelial Function and Cardiac Output: New Methods
The main purpose of this study is to analyse test-retest-reliability of functional quantification of endothelial dysfunction through puls-amplitude-tonometry in patients with heart failure with preserved/reduced ejection…
- Conditions
- Heart Failure, Hypertension, Pulmonary, Hypertension, Diabetic Nephropathies
- Trial name
- NCT02299960
- Testing
- Endo-PAT, NICOM
- Where
- Germany
- Volunteers
- 101 people
- Sponsor
- Charite University, Berlin, Germany
Pulmonary Hypertension
Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin.
- Trial name
- NCT00373360
- Testing
- treprostinil sodium
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Pulmonary Artery Hypertension
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH
Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance ultimately leading to right ventricular (RV) failure.
- Trial name
- NCT03979482
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Laval University
Chronic Kidney Disease, Hemodialysis
Effect of Dry-weight Probing Guided by Lung-Ultrasound on Ambulatory Blood Pressure and Arterial Stiffness in Hemodialysis Patients (LUST Sub-Study)
The most common co-morbidity accompanying Chronic Kidney Disease (CKD) is hypertension, which appears in approximately 80% of all patients with renal dysfunction, whereas its prevalence in general population is remarkably lower…
- Conditions
- Chronic Kidney Disease, Hemodialysis, Hypertension
- Trial name
- LUST ABPM (NCT03058874)
- Testing
- Extra-vascular lung water measurements by ultrasound, Standard protocol of fluid management in hemodialysis
- Where
- 2 sites in Greece, Slovenia
- Volunteers
- 71 people
- Sponsor
- Carmine Zoccali
Hypertension
Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)
The purpose of this study is to test whether the addition of inhaled iloprost is safe and effective in patients with idiopathic pulmonary arterial hypertension who are already being treated with the endothelin receptor antagonist…
- Trial name
- NCT00120380
- Testing
- Aerosolized iloprost
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Hannover Medical School
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
A Study to Evaluate GSK1325760A - a Long-Term Extension Study
The primary objective of this study is to evaluate the safety of long-term administration of GSK1325760A in patients with PAH. The secondary objectives of this study are to evaluate long-term administration of GSK1325760A on…
- Trial name
- NCT00554619
- Testing
- GSK1325760A
- Where
- 11 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Acute and chronic hemodynamic dose-response and safety evaluation of LIQ861 in PAH subjects.
- Trial name
- NCT03884465
- Testing
- Inhaled dry powder treprostinil (LIQ861)
- Where
- 3 sites in France, Germany
- Volunteers
- 15 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years.
- Trial name
- MOVE PAH) (NCT05464095)
- Testing
- mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
Bosentan in Children With Pulmonary Arterial Hypertension
The aim of the study is to demonstrate that the exposure to bosentan in children with idiopathic pulmonary arterial hypertension (PAH) or familial pulmonary arterial hypertension, using a pediatric formulation, is similar to that…
- Trial name
- FUTURE-1 (NCT00319267)
- Testing
- Bosentan
- Volunteers
- 36 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
This study evaluates the long-term safety of Udenafil in Patient with Pulmonary Arterial Hypertension(PAH). All the patients will receive Udenafil for 1-year(48-weeks).
- Trial name
- NCT02304198
- Testing
- Udenafil
- Where
- South Korea
- Volunteers
- 59 people
- Sponsor
- Dong-A ST Co., Ltd.
Pulmonary Arterial Hypertension
Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) can result in right ventricular failure and death. Anakinra has been used in patients with left sided heart failure, and the present study looks to determine if anakinra is safe and effective…
- Trial name
- NCT03057028
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Virginia Commonwealth University
Systemic Sclerosis, Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension in Systemic Sclerosis
The purpose of this study is to evaluate the role of stress echocardiography, compared to standard echocardiography in the early identification of pulmonary arterial hypertension in systemic sclerosis.
- Trial name
- NCT00617487
- Where
- 2 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Pulmonary Hypertension
Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension
Open label extension study to the pivotal efficacy study to assess the safety of sildenafil citrate in patients with pulmonary arterial hypertension
- Trial name
- NCT00159887
- Testing
- Sildenafil citrate
- Where
- 65 sites in United States, Australia and 20 more
- Volunteers
- 260 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension, Pulmonary Arterial
Pulmonary Hypertension Institutional Registry at Hospital Italiano de Buenos Aires
The purpose of this study is to create a registry of patients with Pulmonary Hypertension who received medical care in the Hospital Italiano of Buenos Aires.
- Trial name
- PH-HIBA (NCT01501838)
- Where
- Argentina
- Volunteers
- 200 people
- Sponsor
- Hospital Italiano de Buenos Aires
Pulmonary Hypertension
Fractal Analysis of the Pulmonary Arterial Tree in Pulmonary Hypertension
The investigators propose to confirm that normotensive and hypertensive pulmonary arteries are fractal, as well as define if the FD correlates to disease severity when compared to available data such as six-minute walk and right…
- Trial name
- NCT01135706
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ohio State University
Pulmonary Arterial Hypertension
Crossover Study From Macitentan or Bosentan Over to Ambrisentan
The purpose of this study is to learn more about the safety and effects of switching treatments from bosentan (Tracleer) or macientan (Opsumit) to ambrisentan (Letairis) over 24 weeks in subjects with Connective Tissue Disease…
- Trial name
- Letairis (NCT02885012)
- Testing
- Ambrisentan
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Medical University of South Carolina
Hypertension, Pulmonary
Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study
This study is to investigate the efficacy, safety, and Pharmacokinetics (PK) of Inhaled Iloprost (Ventavis) therapy in Japanese pulmonary arterial hypertension (PAH) patients in Main Treatment Phase (12 weeks) and to investigate…
- Trial name
- IBUKI (NCT01469169)
- Testing
- Iloprost (Ventavis inhaled, BAYQ6256)
- Where
- 18 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension
The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with an ACE inhibitor (captopril) and a beta-blocker (carvedilol) is effective in reverse pulmonary artery…
- Trial name
- NCT00240656
- Testing
- spironolactone captopril carvedilol
- Where
- China
- Sponsor
- Hebei Medical University
Pulmonary Arterial Hypertension
Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension
Despite advances in treatment and corresponding improvements in survival, patients with pulmonary arterial hypertension (PAH) remain highly symptomatic.
- Trial name
- NCT03401476
- Testing
- Morphine Sulfate
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- John Granton